Data sourced from Dakota Private Markets, the private fund performance platform powered by Dakota. Learn More | Request Access
Eli Lilly has closed its acquisition of AtaiBeckley, a clinical-stage biotech developing rapid-acting treatments for depression, in a deal worth up to $3.8 billion. The transaction closed on September 11, 2026, after AtaiBeckley shareholders approved it at a special meeting. Shareholders received $6.75 per share in cash upfront, roughly $2.8 billion in aggregate equity value, plus contingent value rights worth up to another $2.50 per share tied to regulatory milestones, a roughly 40% premium to AtaiBeckley's 30-day average share price ahead of the announcement.
A Pipeline Built Around a Different Kind of Antidepressant
AtaiBeckley's lead program, BPL-003, is an intranasal synthetic form of 5-MeO-DMT designed to treat depression that has not responded to conventional therapy. The compound has FDA Breakthrough Therapy Designation and is now in Phase 3 trials. In earlier Phase 2b studies, patients showed rapid and durable symptom reduction lasting months after a single roughly two-hour clinic visit.
The rest of the pipeline follows the same thesis. VLS-01, a DMT buccal film, is in Phase 2b, while EMP-01, a form of MDMA, is in Phase 2 for social anxiety disorder. AtaiBeckley is also running earlier-stage discovery work on non-hallucinogenic compounds that target the same brain receptor pathway without the psychedelic effects, a distinction that matters for how these drugs eventually get prescribed and reimbursed.
Why Lilly Wanted It
Conventional antidepressants work by adjusting neurotransmitter levels and often take weeks to show any effect, if they work at all for a given patient. AtaiBeckley's compounds are built around a different mechanism entirely: restoring synaptic plasticity and promoting neural growth, which is part of why the effects show up faster and appear to last longer.
For Lilly, this is a pipeline gap it could not close as quickly on its own. Carole Ho, EVP and president of Lilly Neuroscience, said following the close that "treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief." Buying a Phase 3-ready, breakthrough-designated asset gets Lilly into next-generation psychiatric treatment years faster than building the science internally, and with a target population, treatment-resistant depression, that current drugs largely fail to reach.
Want to see deals like this the moment they're announced? Dakota Private Markets tracks 30,000+ private company transactions with structured data on deal type, value, and date, plus daily curated updates from our editorial team. Request Access →
What Happens Now
With the deal closed, AtaiBeckley's pipeline moves fully under Lilly Neuroscience, which has framed the acquisition as a step toward moving psychiatric care away from chronic dosing and toward faster-acting treatment paradigms. The path forward still runs through regulatory milestones as much as clinical ones: two of the three CVR triggers require DEA rescheduling in addition to FDA approval, since these compounds are currently controlled substances. That means Lilly is betting not just on the science but on the regulatory environment continuing to shift toward accommodating psychedelic-derived medicines, a trend that has been building for several years as more Breakthrough Therapy designations have gone to this class of drugs.
If Lilly gets BPL-003 through Phase 3 and rescheduling, it inherits a commercial-ready asset backed by the distribution and prescriber relationships few biotechs can match on their own. That combination, novel mechanism plus large-pharma commercialization muscle, is the bet behind the roughly 40% premium.
What The Founders Built Next
AtaiBeckley traces back to Christian Angermayer, the German entrepreneur and investor who founded the company in 2018 and remains its chairman and largest shareholder. Angermayer built his fortune, estimated by Forbes at over $1 billion, through Apeiron Investment Group, the Malta-based family office and merchant bank he runs that invests across life sciences, fintech, and emerging technology. Apeiron has backed a run of biotech and psychedelic-medicine ventures alongside AtaiBeckley, including Compass Pathways, and has signed a voting agreement supporting the Lilly deal.
Srinivas Rao, AtaiBeckley's co-founder and CEO, will see the company he helped build move under a major pharmaceutical parent, a familiar path for biotech founders but a notable one here given how much of the psychedelic-medicine category AtaiBeckley has helped legitimize with institutional and regulatory audiences.
The Broader Signal
At up to $3.8 billion, this deal tells fund managers something about where large pharma sees the next category of psychiatric drugs heading. Big pharma has been circling psychedelic-derived and neuroplastogenic compounds for a few years, but this is one of the larger bets yet on the category actually reaching approval and commercial scale, not just clinical proof of concept.
It also confirms that family offices with deep, long-term conviction in a therapeutic thesis, the kind of patient capital Apeiron has provided AtaiBeckley since 2018, can still originate and carry a company all the way to a large-pharma exit. For fund managers building relationships with founder-led family offices in life sciences and biotech, that is exactly the kind of allocator behavior worth tracking.
Family offices like Apeiron, built by an operator with a long track record of backing category-defining biotech companies, are exactly the kind of allocators fund managers need to be able to find and reach. Dakota Marketplace tracks family office accounts globally with investment preferences, verified contacts, and real-time intel.
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Dakota Private Markets, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Dakota helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, request access to Dakota Private Markets.
